Skip to main content
. 2022 May 9;12(9):1217. doi: 10.3390/ani12091217

Figure 7.

Figure 7

Mean arterial pressure (MAP) before and after administration of dexmedetomidine (DEX) and/or placebo with time points (5, 10, 15, 20, 25 and 30 min) presenting values after completion of IV application of DEX or placebo. Levobupivacaine was used for both infraorbital and inferior alveolar blocks. Values are expressed as median and IQR. B, baseline value, prior to administration of oral blocks; BL, immediately after administration of oral blocks; IV1, after one min/completion of IV application of DEX or placebo; IV2, after two min/completion of IV application of DEX or placebo; LB + DEX IA, dogs (n = 10) which received levobupivacaine and dexmedetomidine perineurally into the submucosa at the opening of the mandibular foramen; LB + DEX IO, dogs (n = 10) which received levobupivacaine and dexmedetomidine perineurally into the infraorbital canal; LB + DEX IV, dogs (n = 10) which received levobupivacaine perineurally and dexmedetomidine IV (positive control); LB + PLC IV, dogs (n = 10) which received levobupivacaine perineurally and placebo IV (negative control); MAP, mean arterial pressure. * significant difference (p < 0.05) between the LB + PLC IV and LB + DEX IV groups. † significant difference (p < 0.05) between the LB + PLC IV and LB + DEX IA groups. ¢ significant difference (p < 0.05) between the LB + DEX IV and LB + DEX IA groups. ¥ significant difference (p < 0.05) between the LB + DEX IV and LB + DEX IO groups.